KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Minority Interest (2017 - 2026)

Amneal Pharmaceuticals has reported Minority Interest over the past 9 years, most recently at $77.3 million for Q4 2025.

  • For Q4 2025, Minority Interest rose 31647.76% year-over-year to $77.3 million; the TTM value through Dec 2025 reached $77.3 million, up 31647.76%, while the annual FY2025 figure was $77.3 million, 31647.76% up from the prior year.
  • Minority Interest for Q4 2025 was $77.3 million at Amneal Pharmaceuticals, up from $67.8 million in the prior quarter.
  • Over five years, Minority Interest peaked at $77.3 million in Q4 2025 and troughed at -$245000.0 in Q4 2024.
  • A 5-year average of $36.1 million and a median of $29.8 million in 2023 define the central range for Minority Interest.
  • Biggest five-year swings in Minority Interest: tumbled 100.59% in 2024 and later skyrocketed 31647.76% in 2025.
  • Year by year, Minority Interest stood at $16.9 million in 2021, then soared by 47.57% to $24.9 million in 2022, then surged by 65.51% to $41.3 million in 2023, then tumbled by 100.59% to -$245000.0 in 2024, then skyrocketed by 31647.76% to $77.3 million in 2025.
  • Business Quant data shows Minority Interest for AMRX at $77.3 million in Q4 2025, $67.8 million in Q3 2025, and $65.8 million in Q2 2025.